Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment

• Дата: 2023
• Автори: Chekhun, V.F., Borikun, T.V., Bazas, V.М., Andriiv, A.V., Klyusov, O.М., Yalovenko, T.М., Lukianova, N.Yu.
• Формат: Стаття
• Мова: English
• Опубліковано: PH Akademperiodyka 2023
• Теми: breast cancer; miRNA; resistance
• Онлайн доступ: https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-2
• Назва журналу: Experimental Oncology

Summary. Aim: To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes. Materials and Methods: We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast cancer patients using real-time polymerase chain reaction. Each case was characterized by TMN criteria using morphological and immunohistochemical analyses. Results: Serum levels of miR-205 and -375 are associated with the response of luminal A tumors and miR-205 and -21 with the response of luminal B tumors to neoadjuvant polychemotherapy in fluorouracil + doxorubicin + cyclophosphamide and doxorubicin + cyclophosphamide regimens. In addition, we found correlation of miR-155, -182, -199a, -375 with 3-year relapse-free survival of patients. Based on the obtained data, we developed innovative prognostic and predictive panels to assess the drug sensitivity of tumors and lower the risk of breast cancer recurrence, which would significantly improve the treatment outcomes and the quality of life of patients. Conclusions: Serum levels of miR-155, -182, -199a, -205, -375 can be used as predictive and prognostic panel for monitoring BC course in Ukrainian population.